Er-Kim Extends Exclusive Distribution Agreement with Ascendis Pharma AS to Expand Commercialization of Its Endocrinology Portfolio to Eurasian Markets
| ETAGX Fund | USD 49.46 0.22 0.44% |
Slightly above 61% of Eventide Gilead's investor base is looking to short. The analysis of overall sentiment of trading Eventide Gilead mutual fund suggests that many investors are alarmed at this time. Eventide Gilead's investing sentiment can be driven by a variety of factors including economic data, Eventide Gilead's earnings reports, geopolitical events, and overall market trends.
Eventide |
Broadened agreement now addresses the unmet need for novel rare endocrinology disease therapies in Central and Eastern Europe and Eurasian marketsATHENS, Greece and ALMATY, Kazakhstan, Dec. 10, 2024 -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today announced that it has extended its exclusive agreement with Danish biopharmaceutical company Ascendis Pharma AS to commercialize three rare endocrinology
Read at finance.yahoo.com
 |
Eventide Gilead Fundamental Analysis
We analyze Eventide Gilead's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eventide Gilead using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eventide Gilead based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Year To Date Return
Year To Date Return Comparative Analysis
Eventide Gilead is currently under evaluation in year to date return among similar funds. Year to Date Return (YTD) is the total return generated from holding a security from the beginning of the current fiscal year. In other words, YTD Return represents the capital appreciation of your investments from the start of the current fiscal year.
Eventide Gilead Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Eventide Gilead mutual fund to make a market-neutral strategy. Peer analysis of Eventide Gilead could also be used in its relative valuation, which is a method of valuing Eventide Gilead by comparing valuation metrics with similar companies.
Peers
Eventide Gilead Related Equities
| ETAEX | Eventide Exponential | 4.19 | ||||
| ETARX | Eventide Core | 0.61 | ||||
| ETCRX | Eventide Core | 0.49 | ||||
| ETAHX | Eventide Healthcare | 0.06 | ||||
| ETCHX | Eventide Healthcare | 0.07 | ||||
| ETABX | Eventide Limited | 0.10 | ||||
| ETADX | Eventide Global | 0.21 | ||||
| ETAMX | Eventide Multi | 0.28 | ||||
| ETCMX | Eventide Multi | 0.28 |
Other Information on Investing in Eventide Mutual Fund
Eventide Gilead financial ratios help investors to determine whether Eventide Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Eventide with respect to the benefits of owning Eventide Gilead security.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |